Chronic heart failure of ischemic origin complicated by concomitant diabetes mellitus type 2 is characterized by significant decreasing of the quality of life in general, and of physical and psychological welfare, self-service and independence of action, same as personal implementation particularly. Inclusion of telmisartan to the scheme of complex treatment of the patients with chronic heart failure and diabetes mellitus type 2 results in the improvement of the patients’ quality of life as well as its main component
